CF INDUSTRIES HOLDINGS INC (CF) 101.5 -1.98 (-1.91%)
101.5 -1.98 (-1.91%)
US1252691001 - Common Stock - After market: 101.5 0 (0%)
Fundamental Rating
We assign a fundamental rating of 7 out of 10 to CF. CF was compared to 119 industry peers in the Chemicals industry. CF scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on CF. This makes CF very considerable for value investing!.
Profitability
Profitability Rating
CF has a Return On Assets of 24.03%. This is amongst the best returns in the industry. The industry average is 5.15%. CF outperforms 97% of its industry peers.
CF has a Return On Equity of 71.80%. This is amongst the best returns in the industry. The industry average is 19.46%. CF outperforms 96% of its industry peers.
CF's Profit Margin of 28.70% is amongst the best returns of the industry. CF outperforms 96% of its industry peers. The industry average Profit Margin is 6.53%.
The Piotroski-F score of CF is 9.00. This is a very strong score and indicates great health and profitability for CF.
VS Industry
ROA (24.03%) VS Industry: 97% outperformed.
-1,527.37
271.00
ROE (71.8%) VS Industry: 96% outperformed.
0.05
225.47
Profit Margin (28.7%) VS Industry: 96% outperformed.
-160,314.80
85.23
Valuation
Valuation Rating
The Price/Earnings Ratio is 6.37, which indicates a rather cheap valuation of CF.
Compared to an average industry Price/Earning Ratio of 11.07, CF is valued a bit cheaper than its industry peers.
The Forward Price/Earnings Ratio of 7.01 indicates a rather cheap valuation of CF.
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
When comparing the Enterprise Value to EBITDA ratio of CF to the average industry ratio of 9.28, CF is valued rather cheaply. CF is also cheaper than 87% of the companies listed in the same industry.
When comparing the current price to the book value of CF, we can conclude it is valued correctly. It is trading at 4.48 times its book value.
When comparing the price book ratio of CF to the average industry price book ratio of 1.97, CF is valued more expensive than its industry peers. 80% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (6.37) VS Industry: 73% outperformed.
569.57
1.74
Price/Book (4.48) VS Industry: 20% outperformed.
25.28
0.03
Enterprise Value/ EBITDA (3.28) VS Industry: 87% outperformed.
571.97
0.28
Growth
Growth Rating
CF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1022.54%, which is quite impressive.
Measured over the past 5 years, CF shows a very strong growth in Earnings Per Share. The EPS has been growing by 55.62% on average per year.
Looking at the last year, CF shows a very strong growth in Revenue. The Revenue has grown by 118.00%.
Measured over the past 5 years, CF shows a quite strong growth in Revenue. The Revenue has been growing by 12.15% on average per year.
Based on estimates for the next 5 years, CF will show a decrease in Earnings Per Share. The EPS will decrease by -3.00% on average per year.
The Revenue is expected to decrease by -6.31% on average over the next 5 years.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 55.62% | 52.48% | 1022.54% | 331.53% | 83.72% | 24.5% | -3% |
| Revenue | 12.15% | 13.86% | 118% | 80.07% | 23.44% | 4.93% | -6.31% |
Health
Health Rating
CF has a Current Ratio of 2.66. This indicates that CF is financially healthy and has no problem in meeting its short term obligations.
CF is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 2.07.
CF has a Quick Ratio of 2.30. This indicates that CF is financially healthy and has no problem in meeting its short term obligations.
CF is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.32.
An Altman-Z score of 4.24 indicates that CF is not in any danger for bankruptcy at the moment.
The Altman-Z score of CF is much better than the industry average of 2.68.
The Piotroski-F score of CF is 9.00. This is a very strong score and indicates great health and profitability for CF.
The Debt to Equity ratio of CF is in line with the industry averages.
VS Industry
Debt/Equity (0.67) VS Industry: 42% outperformed.
19.13
0.00
Quick Ratio (2.3) VS Industry: 77% outperformed.
0.00
65.94
Current Ratio (2.66) VS Industry: 68% outperformed.
0.00
65.94
Altman-Z (4.24) VS Industry: 79% outperformed.
-1,443.46
137.48
Dividend
Dividend Rating
CF pays out 9.15% of its income as dividend. This is a sustainable payout ratio.
CF has been paying a dividend for at least 10 years, so it has a reliable track record.
With a Yearly Dividend Yield of 1.47%, CF has a reasonable but not impressive dividend return.
CF's Dividend Yield is slightly below the industry average, which is at 2.40.
CF's Dividend Yield is slightly below the S&P500 average, which is at 2.43.
VS Industry
Dividend Yield (1.47%) VS Industry: 31% outperformed.
0.35
22.94
CF INDUSTRIES HOLDINGS INC101.5
NYSE:CF (12/6/2022, 3:31:01 PM)-1.98 (-1.91%)
| GICS Sector | Materials | ||
| GICS IndustryGroup | Materials | ||
| GICS Industry | Chemicals | ||
| Earnings (Last) | 11-02 2022-11-02/amc | Earnings (Next) | 02-13 2023-02-13 |
| Ins Owners | 0.45% | Inst Owners | 204.01% |
| Market Cap | 19.91B | Analysts | 75.71 |
| PE | 6.37 | Fwd PE | 7.01 |
| PEG (NY) | 0.02 | PEG (5Y) | 0.11 |
| P/S | 1.79 | P/B | 4.48 |
| EV/EBITDA | 3.28 | ||
| Dividend Yield | 1.47% | Dividend Growth | N/A |
| DP | 9.15% | Ex-Date | 11-14 2022-11-14 (0.4) |
| EPS 1Y | 1022.54% | EPS 3Y | 52.48% |
| EPS 5Y | 55.62% | EPS growth Q2Q | 363.95% |
| EPS Next Y | 331.53% | EPS Next 2Y | 83.72% |
| EPS Next 3Y | 24.5% | EPS Next 5Y | -3% |
| Revenue growth 1Y | 118% | Revenue growth 3Y | 13.86% |
| Revenue growth 5Y | 12.15% | Revenue growth Q2Q | 70.41% |
| Revenue Next Year | 80.07% | Revenue Next 2Y | 23.44% |
| Revenue Next 3Y | 4.93% | Revenue Next 5Y | -6.31% |
| Current Ratio | 2.66 | Quick Ratio | 2.3 |
| Altman-Z | 4.24 | F-Score | 9 |
| Debt/Equity | 0.67 | WACC | 7.58% |
| ROIC/WACC | 8.39 | ||
| ROA | 24.03% | ROE | 71.8% |
| ROICexgc | 63.59% | ROIC | 40.63% |
| PM | 28.7% | OM | 49.71% |
| Asset Turnover | 0.84 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA